

November 14, 2019

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

**Trading Symbol: ZOTA** 

Sub: Outcome of Board Meeting held on Thursday, November 14, 2019

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Board of Directors of Zota Health Care Limited (the "Company") in its Meeting held on Thursday, November 14, 2019 at 02:00 P.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat – 395002 have, *inter alia*, discussed and approved the following business:

1. Considered and approved unaudited standalone and consolidated financial results for the quarter and half year ended on September 30, 2019 along with Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (Annexure – I).

Further, unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company is listed i.e. at <a href="https://www.nseindia.com">www.nseindia.com</a> and on Company's website at <a href="https://www.zotahealthcare.com">www.zotahealthcare.com</a>

The Board meeting concluded at 07:00 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya

(Company Secretary & Compliance Officer)

Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India

Ph: +91 261 2397122 /

7

## SHIVANGI PAREKH & CO.

#### CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

То

The Board of Directors of Zota Health Care Limited

- We have reviewed the accompanying statement of unaudited financial results of Zota Health Care Limited (the "Company") for the quarter and half year ended September 30, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Attention is drawn to Note no.3 of the Statement which states that the Comparative figures of quarter ended June 30, 2019 and September 30, 2018 as reported in the accompanying Statement have been restated by the management of the Company and prepared by exercising necessary due diligence to ensure that the financial results reflect true and fair view of Company's affairs but have not been subjected to review.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date:14/11/2019

Place: Surat

SURAT SURAT

For Shivangi Parekh & Co. Chartered Accountants ICAI FRN: 131449W

CA. Shivangi Mehta Proprietor

M. No.118936

UDIN: 191189 36 AAAACX 2524

## SHIVANGI PAREKH & CO.

#### CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Zota Health Care Limited

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Zota Health Care Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter and half year ended September 30, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (the "Regulation").
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Attention is drawn that the Comparative figures of quarter ended June 30, 2019 as reported in the accompanying Statement have been restated by the Company's Board of Directors, but have not been subjected to review.

Further Attention is drawn to Note no. 7 of the Statement which states the Company has incorporated wholly owned subsidiary company in Sri Lanka during the second half of Financial Year 2018-19, prior this period Company does not have any wholly owned subsidiary company. So, accordingly no consolidated accounts for the quarter and half year ended September 30, 2018 and Consolidated Cash Flow Statements for the half year ended September 30, 2018 have been prepared for the quarter and half year ended September 30, 2018.

## SHIVANGI PAREKH & CO.

#### CHARTERED ACCOUNTANTS

- 4. The Statement includes the results of the following entities:
  - a. Zota Health Care Limited (Parent)
  - b. Zota Healthcare Lanka (Pvt) Ltd (Subsidiary)
- 5. Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial statements of the subsidiary included in the consolidated unaudited financial results that reflect total assets of Rs.76,043/- as at 30.09.2019 and total revenues of Rs. Nil and Rs. Nil, total net loss after tax of Rs. 3950 and Rs. 5378 and total comprehensive loss of Rs.3950 and Rs. 5378, for the quarter and half year ended 30.09.2019, respectively, and cash flows (net) of Rs. 77623 for the half year ended 30.09.2019, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Parex

Our conclusion on the Statement is not modified in respect of the above matters.

For Shivangi Parekh & Co. Chartered Accountants

ICAI FRN: 131449W

CA. Shivangi Mehta

Proprietor

M. No.118936

UDIN: 1911 8936 AAAACY 4273

Date:14/11/2019 Place: Surat



# ZOTA HEALTH CARE LIMITED Standalone Financial Statements

Statement of Profit & Loss for the Quarter and Half year ended 30th September, 2019

		Quarter Ended				Half Year Ended	
		30/09/2019 30/06/2019 30/09/2018			30/09/2019	30/09/2018	Year Ended 31/03/2019
	Particulars	(Unaudited)	(Unaudited) (Refer Note-3)	(Unaudited) (Refer Note-3)	(Unaudited)	(Unaudited)	(Audited)
ı. II.	Revenue from Operations Other Incomes	252,874,698 3,749,036	216,818,937 2,980,895	242,229,485.00 6,219,688.00	469,693,635 6,729,930	432,655,522 10,025,659	856,294,30 15,447,26
81.	Total Revenue	256,623,733	219,799,832	248,449,173	476,423,565	442,681,181	871,741,57
IV.					47071233353		012,142,31
IV.	Expenses: Cost of Materials Consumed: Purchases of Stock-in-Trade Changes in Inventories of Finished Goods, Work-in-Progress and Stock-	17,970,286 145,127,967	36,245,029 104,758,508	38,560,242.00 155,505,158.00	54,215,315 249,886,475	48,546,492 294,693,599	115,100,07 527,635,05
	in-Trade Employee Benefit Expenses	16,385,934 25,898,652	8,946,829 24,351,752	(33,785,470.00) 22,668,241.00	25,332,763 50,250,404	(60,287,112) 40,275,135	(72,596,8 88,919,0
	Finance Costs Depreciation / Amortisation and Depletion Expense	102,190 3,204,699	130,019 3,003,679	23,852.00 3,519,025.14	232,210 6,208,378	71,528 7,593,373	368,0 13,942,2
	Other Expenses	33,293,988	33,986,014	25,713,449.00	67,280,002	50,996,426	119,781,4
	Total Expenses	241,983,716	211,421,830	212,204,497	453,405,546	381,889,441	793,149,1
٧.	Profit before Exceptional items and tax from continuing operations (III-IV)	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,4
VL VII.	Exceptional Items Profit before Extraordinary Items and Tax (V - VI)	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,4
VIII. IX.	Extra Ordinary Items Profit/(loss) before exceptional items and tax (VII-VIII)	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,4
X. XI.	Exceptional items Profit/(loss) before tax	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,4
XII.	Tax Expense: (1) Current tax	3,680,622	2,107,643	11,804,891	5,788,265	19,796,794	23,242,5
	(1.1) i.T. & DD Tax Provision Created Short/ excess (2) Deferred Tax	(48,664)	26,020 (626,712)	131,604 279,809	26,020 (675,376)	220,744 469,338	233,5 402,8
XIII.	Profit/ (Loss) for the period from Continuing Operations (XI - XII)	10,910,731	5,617,628	24,587,989	16,528,359	41,243,539	55,519,1
KIV.	Profit/(loss) before tax from discontinued operations		\			10	
XV.	Tax Expense of discontinued Operations						
XVI.	Profit/ (Loss) from Discontinued Operations (after Tax) (XIV - XV)					a .	12
CVII.	Profit/ (Loss) for the Year Other Comprehensive Income	10,910,731	5,617,628	24,587,989	16,528,359	41,243,539	55,519,1
	A (i) Items that will not be reclassified to Statement of profit and loss	458,729	1,150,292		1,609,021		(921,7
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss  B (i) Items that will be reclassified to Statement of profit	(115,453)	(289,505)		(404,958)	30	256,4
	and loss (ii) Income Tax relating to items that will be reclassified						8
	to profit and loss Other comprehensive income for the year, net of tax	343,276	860,787		1 204 052		
	Total comprehensive income for the year (XVII + XVIII)	11,254,008	6,478,414	24,587,989	1,204,063 17,732,422	41,243,539	(665,2 54,853,8
	Profit attributable to: Owners of the parent						
	Non-controlling interest						
	Other comprehensive income attributable to: Owners of the parent						
	Non-controlling interest	**				1	
	Earnings per equity share of face value of ₹ 10 each (1) Basic (in ₹)	0.44	0.23	1.00	0.67	1.68	2.
	(2) Diluted (in ?)	0.44	0.23	1.00	0.67	1.68	2.

For and on behalf of the Board

(Whole Time Director) Himanshu M. Zota (Din: 01097722)

(Managing Director) Moxesh K. Zota (Din: 07625219) 8D, Lai Bunglow, Athwalines

Chief Financial Office

Date:14/11/2019 Place : Surat Shivangi Parekh & Co. Chartered Accountant

CA. Shivangi Mehta Proprietor M. No. 118936 Firm No. 131449W

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

## Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

Parek

N.



#### ZOTA HEALTH CARE LIMITED

**Consolidated Financial Statements** 

Statement of Profit & Loss for the Quarter and Half year ended 30th September, 2019

(All Amounts in ₹)

		Quarter Ended 30/09/2019 30/06/2019 30/09/2018		Half Year Ended 30/09/2019 30/09/2018		Year Ended	
	Particulars	(Unaudited)	30/06/2019 (Unaudited)	(Unaudited) (Refer Note-7)	(Unaudited)	(Unaudited) (Refer Note-7)	31/03/2019 (Audited)
7		252,874,698	216,818,937	(neses more-7)	469,693,635	(neier more-r)	856,294,307
L II.	Revenue from Operations Other Incomes	3,749,036	2,980,895		6,729,930		15,447,264
HL.		256,623,733	219,799,832		476,423,565		871,741,571
HI.	Total Revenue	256,623,733	219,799,832		476,423,363		8/1,/41,5/
IV.	Expenses:	A A					
	Cost of Materials Consumed:	17,970,286	36,245,029		54,215,315		115,100,07
	Purchases of Stock-in-Trade	145,127,967	104,758,508		249,886,475		527,635,05
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in	16,385,934	8,946,829		25,332,763		(73 505 00)
	Trade Employee Benefit Expenses	25,898,652	24,351,752		50,250,404		(72,596,80° 88,919,07°
	Finance Costs	102,190	131,446		233,635		368,02
	Depreciation / Amortisation and Depletion Expense	3,204,699	3,003,679		6,208,378		13,942,28
	Other Expenses	33,297,938	33,986,014		67,283,954		119,816,45
	Total Expenses	241,987,666	211,423,256		453,410,924		793,184,168
7752							
V.	Profit before Exceptional items and tax from continuing operations	** *** ***	0.375.575		*******		70.777.10
VI	(III-IV) Exceptional Items	14,636,067	8,376,576		23,012,642		78,557,40
VII	Profit before Extraordinary Items and Tax (V - VI)	14,636,067	8,376,576		23,012,642		78,557,40
VIII.	Extra Ordinary Items		125				
ıx	Profit/(loss) before exceptional items and tax (VII-VIII)	14,636,067	8,376,576		23,012,642		78,557,40
X.	Exceptional items	14,030,007	8,370,370		23,012,042		70,337,40
XI.	Profit/(loss) before tax from continuing operations(IX-X)	14,636,067	8,376,576		23,012,642		78,557,40
XII.	Tax Expense:	14,030,007	0,5,0,5,0		25,022,042		10,557,40
	(1) Current tax	3,680,622	2,107,642.88		5,788,265		23,242,53
	(1.1) I.T. & DD Tax Provision Created Short/ excess	NEW (1997)	26,020.00		26,020		233,58
	(2) Deferred Tax	(48,664)	(626,712.00)		(675,376)		402,84
XIII.	Profit/ (Loss) for the period from Continuing Operations (XI - XII)	10,906,781	5,616,201		16,522,981		55,484,13
XIV.	Profit/(loss) before tax from discontinued operations						
xv.	Tax Expense of discontinued Operations						
	120						
XVL	Profit/ (Loss) from Discontinued Operations (after Tax) (XIV - XV)						
XVII	Profit/ (Loss) for the Year	10,906,781	5,616,201		16,522,981		55,484,13
XVIII		500000000000000000000000000000000000000	POTATO CANADO				1 22242
	A (i) Items that will not be reclassified to Statement of	M. W. C.	Del Marcollo de del		100000000000000000000000000000000000000		
	profit and loss	458,729	1,150,292		1,609,021		(921,71
	(ii) Income Tax relating to items that will not be	(115.453)	(200 505)		1404.0581		255.42
	reclassified to Statement of profit and loss  B (i) Items that will be reclassified to Statement of profit	(115,453)	(289,505)		(404,958)		256,42
	and loss	(9,269.01)	29.01		(9,240)	_102	1,48
	(ii) Income Tax relating to items that will be reclassified	(2)2021021			(2,2,10)		
	to profit and loss (iii)Fair value changes on investments, net						(41
	Other comprehensive income for the year, net of tax	334,007	860,816		1,194,823		(664,22
	Total comprehensive income for the year (XVII + XVIII)	11,240,789	6,477,017		17,717,804		54,819,90
	Profit attributable to:	2 2	00. 88 1				
	Owners of the parent	10,906,781	5,616,201		16,522,981		55,484,13
	Non-controlling interest	20,500,701	3,010,101		10,322,301		33,704,13
	Other comprehensive income attributable to:						
	Owners of the parent Non-controlling interest	334,007	860,816		1,194,823		(664,22
	Earnings per equity share of face value of ₹ 10 each						
	(1) Basic (in f)	0.44	0.23		0.67		2.2
	(2) Diluted (in ?)	0.44	0.23		0.67		2.2

For and on behalf of the Board

Whole Time Director) Himanshu M. Zota (Din: 01097722) 34,Ichhanath Umra,

(Managing Director) Moxesh K. Zota (Din: 07625219) 8D,Lal Bunglow, Athwalines

ampany Secretary Chief

Chief Financial Office

Date:14/11/2019 Place : Surat

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com Shivangi Parekh & Co. Chartered Accountants

Jangi Parekh

ered Acco

CA. Shivangi Mehta Proprietor M. No. 118936 Firm No. 131449W

## Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

¥





#### Notes:

- 1 The above financial results for the quarter and half year ended September 30, 2019 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 14, 2019.
- 2 The Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2019.
- The Company has migrated to the main Board of National Stock Exchange w.e.f. August 19, 2019 accordingly the Company has not prepared financial results for the previous quarters. However, Comparative figures of quarter ended June 30, 2019 and September 30, 2018 have been restated by the management of the Company and prepared by exercising necessary due diligence to ensure that the financial results reflect true and fair view of Company's affairs. Financial results for the quarter ended June 30, 2019 and September 30, 2018 have not been subjected to limited review report of auditor.
- 4 The Company has evaluated its Operating segment in accordance with IND AS 108 and has concluded that it is engaged in a single operating segment.
- 5 During the reporting period; on July 29, 2019 Company has issued 7016975 bonus shares in the ratio of 4:10 [i.e. 4 (Four) fully paid up equity shares for every 10 (Ten) equity shares held.] Post this issue Earning Per Share (EPS) for all the reporting period have been restated as per IND AS 33.
- 6 The consolidated results include the result of Company's wholly owned subsidiary company Zota Healthcare Lanka (Pvt) Ltd.
- 7 The Company has incorporated wholly owned subsidiary company in Sri Lanka during the second half of Financial Year 2018-19, prior this period Company does not have any wholly owned subsidiary company. So, accordingly no consolidated accounts for the quarter and half year ended September 30, 2018 and Consolidated Cash Flow Statements for the half year ended September 30, 2018 have been prepared for the quarter and half year ended September 30, 2018.
- 8 Tax expenses for the quarter and half year ended September 30, 2019 have been calculated as per Taxation Laws (Amendment) Ordinance 2019, the income-tax is calculated at the reduced rate from the current financial year.
- 9 Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.
- 10 On April 1, 2019, the Company has adopted IND AS 116, Leases, using modified retrospective method. Accordingly, the comparatives have not been retrospectively adjusted. The adoption of IND AS 116, did not have any material impact on the standalone results for Quarters ended September 30, 2019 and June 30, 2019 and Half-year ended on September 30, 2019.





## Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com

#### Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India

Ph: +91 261 2397122

CIN: L24231GJ2000PLC038352



#### ZOTA HEALTH CARE LIMITED Balance Sheet as at 30th September, 2019

		*********		(All Amounts in ₹)		
		CONSOLID		STANDALONE		
	Particulars	As at	As at	As at	As at	
	The second secon	30th September,2019	31st March, 2019	30th September,2019	31st March, 2019	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	
	SSETS			1		
Anne State of the Land	TO THE COURSE OF	1	1			
	Ion-Current Assets	22.22.22.22				
	roperty, plant and equipment	79,009,206	78,930,320	79,009,206	78,930,32	
102	ntangible Assets	18,277,518	18,824,544	18,277,518	18,824,54	
0.00	Capital work-in-progress	2,491,838	2,590,476	2,491,838	2,590,47	
"	ntangible assets under development	12,933,333	12,933,333	12,933,333	12,933,33	
F	inancial Assets			1		
	(i) Investments	151,542,230	156,116,120	151,628,910	156,202,80	
	(iii) Loans	2,682,791	2,929,791	2,682,791	2,929,79	
C	Other Non-current assets		-	-,,	7,,	
31 023	otal Non-Current assets	266,936,915	272,324,583	267,023,595	272,411,26	
(2)	current Assets					
	nventories	200 222 520	225 422 244	202222	2021000000	
	inancial Assets	289,223,530	325,123,918	289,223,530	325,123,91	
1	10.000,000,000,000,000		22222222	44.000		
- 1	(i) Trade Receivables	269,690,939	220,964,038	269,690,939	220,964,03	
	(ii) Cash and Cash Equivalents	242,266	179,302	166,222	179,30	
- 1	(iii) Bank balance other than cash and cash equivalents	12,461,270	16,763,205	12,461,270	16,763,20	
- 1	(iv) Loans	47,045,863	34,380,949	47,045,863	34,380,94	
lo	Other Current Assets	38,102,188	26,330,122	38,102,188	26,330,12	
T	otal Current assets	656,766,055	623,741,532	656,690,012	623,741,53	
T	otal Assets	923,702,970	896,066,116	923,713,608	896,152,79	
E	QUITY AND LIABILITIES					
				1		
	quity	1	1	1		
100	) Equity Share capital	245,603,270	175,433,520	245,603,270	175,433,52	
	ii) Other Equity	431,758,250	513,818,636	431,805,671	513,852,61	
Т	otal Equity	677,361,520	689,252,156	677,408,941	689,286,13	
L	labilities					
N	ion-Current Liabilities	1	1			
F	inancial Liabilities	1	i i			
	(i) Borrowings	- 1			72	
P	rovisions	7,669,115	7,564,955	7,632,331	7,564,95	
(1)	Peferred tax liabilities (Net)	1,821,899	1,146,522	1,821,899	1,146,52	
	otal non-current liabilities	9,491,014	8,711,477	9,454,230	8,711,47	
6	urrent liabilities		STORTS AND EVEN AND E	0.0000000000000000000000000000000000000		
	inancial Liabilities	1				
(2)	2000	4				
(2)	(i) Borrowings	1		100		
- 1	(ii) Trade payables	*	1			
- 1	- Total oustanding dues of micro enterprises and small					
- 1	enterprises	38,950,369	2,044,021	38,950,369	2,044,02	
	- Total Oustanding dues of Creditors other than micro enterprises	100,000				
	and small enterprises	144,831,671	159,639,665	144,831,671	159,639,66	
1.0	ther Current liabilities	12,851,643	5,161,656	12,851,643	5,248,33	
100	rovisions	40,216,754	31,257,140	40,216,754	31,223,16	
	otal current liabilities	236,850,437	198,102,482	236,850,437	198,155,18	
	otal Liabilities	246,341,451	206,813,960	246,304,667	206,866,66	
T	otal Equity and Liabilities	923,702,971	896,066,116	923,713,608	896,152,79	

For and on behalf of the Board

Kersy (Whole Time Director) Himanshu M. Zota (Din: 01097722) 34,Ichhanath Umra,

(Managing Director) Moxesh K. Zota (Din: 07625219) 8D,Lal Bunglow, Athwalines,

Company Secretary Ashvin Variya

Chief Financial Officer Viral Mandviwala

Qua

Date:14/11/2019 Place: Surat

## Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

Shivangi Parekh & Co. **Chartered Accountants** 

CA. Shivangi Mehta

Proprietor

M. No. 118936 Firm No. 131449W Parek

## Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com

Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352



ZOTA HEALTH CARE LIMITED

Cash Flow Statement For the Half Year Ended 30th September, 2019

(Amount in 2)

			lidated	Standalone		
		Half year ended	Half year ended	Half year ended	Half year ended	
	PARTICULARS		30th September, 2019 (Unaudited)	(Unaudited) (Refer Note-7)	30th September, 2019 (Unaudited)	30th September, 2018 (Unaudited)
A	CASH FLOW FROM OPERATING ACTIVITIES					_
	Net Profit Before Tax as per Statement of Profit and Loss		22.012.542		A MORA DE CONTA DE CO	
	Adjusted for:		23,012,642		23,018,020	60,791,74
	Exceptional items					
	Depreciation / Amortisation and Depletion Expense		6,208,378			
	Interest on Unsecured loan		0,200,376		6,208,378	7,593,3
	Interest on Fixed Deposits		(5,492,806)		/F #03 0001	4,33
	Interest on GEB Deposits		23,450	j.	(5,492,806)	(8,635,3
	Operating Profit before Working Capital Changes		23,751,664		23,450	
	Adjusted for:		). (main main m)	8	23,757,042	59,754,1
	Trade Payables		22,098,354	1	22,098,354	27 200 0
	Provisions-Current Liabilities		10,560,572		10,602,614	41,692,0
	Borrowings-Current Liabilities			1	10,002,014	(18,520,7)
	Provisions - Non-Current		104,160	1	67,376	2,209,8
	Current Liabilities		7,689,987		7,603,307	9,298,20
	Trade Receivables		(48,726,901)		(48,726,901)	(33,057,6
	Loans		(12,664,914)		(12,664,914)	25,855,4
	Inventories		35,900,388		35,900,388	(69,593,4
1	Other Current Assets		(11,772,066)		(11,772,066)	(14,086,3
	Changes in Working Capital	1	3,189,580		3,108,158	(56,202,66
	Cash Generated from Operations		26,941,243		26,865,199	
	3-17		200000000000000000000000000000000000000		20,003,133	3,551,44
	Taxes Paid	1	(6,219,243)		(6,219,243)	(20,017,53
	Net Cash Flow from/(Used in) Operating Activities	(A)	20,722,000		20,645,956	(16,466,09
ं	CASH FLOW FROM INVESTING ACTIVITIES	1				
-	Purchase of Intangible Assets	1				
-	Decrease in Long Term Loans & Advances	i	247,000			
-	Interest on Fixed Deposits		5,492,806	1	247,000	
-	Interest on GEB Deposits	1	(23,450)	1	5,492,806	8,635,33
١		i	(25,755)	1	(23,450)	1.00
- 1	Purchase of Tangible Assets	1	(5,641,601)	1	(5,641,601)	U2 007 0
1	Non-current investments		4,573,890	1	4,573,890	(10,997,24
	Net Cash Flow (Used in) Investing Activities	(B)	4,648,645		4,648,645	76,874,77 74,512,86
:	CASH FLOW FROM FINANCING ACTIVITIES				20000000	7,700,000
1	Interest on Unsecured Loan		1	1	1	
1	Dividend Paid	1				(4,32
1	Tax on Dividend		(24,560,327)	1	(24,560,327)	(52,630,05
1	Net Cash Flow from / (Used in) Financing Activities	101	(5,049,289)		(5,049,289)	(10,714,24
	The second many force of the second seconds	(c)	(29,609,616)		(29,609,616)	(63,348,62
	Net Increase/(Decrease) in Cash & Cash Equivalents		quarteres		T	
		(A+B+C)	(4,238,971)		(4,315,015)	(5,301,85
	Opening Balance of Cash and Cash Equivalents		33,705,709		16,942,506	24,620,92
	Closing Balance of Cash and Cash Equivalents		12 702 525			
		1	12,703,536		12,627,492	19,319,068

For and on behalf of the Board

(Whole Time Director) Himanshu M. Zota (Din: 01097722)

(Managing Director) Moxesh K. Zota (Din: 07625219) Lal Bunglow, Athwaline

Company Secretary

Chief Financial Officer

Date:14/11/2019 Place : Surat Shivangi Parekh & Co.

CA. Shivangi Mehta Proprietor M. No. 118936 Firm No. 131449W



# Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com

Web: www.zotahealthcare.com

#### Plant:

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

4

CIN: L24231GJ2000PLC038352